×
About 2,668 results

ALLMedicine™ Chronic Myelogenous Leukemia Center

Research & Reviews  826 results

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04795427

Nov 17th, 2021 - The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of asciminib versus best available therapy (BAT) in Chinese patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP)...

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single cen...
https://doi.org/10.4103/jpgm.JPGM_781_20
Journal of Postgraduate Medicine; Bommannan KB, Naseem S et. al.

Nov 9th, 2021 - Despite the impressive responses achieved with tyrosine kinase inhibitor (TKI) therapy, treatment resistance develops in 16-33% of patients of chronic myelogenous leukemia (CML). Of the BCR-ABL1 dependent mechanisms, mutations in the tyrosine kina...

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
https://clinicaltrials.gov/ct2/show/NCT05061017

Nov 9th, 2021 - Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H...

Myelodysplastic Syndrome (MDS) Clinical Presentation
https://emedicine.medscape.com/article/207347-clinical

Nov 9th, 2021 - History The development of myelodysplastic syndrome (MDS) may be preceded by a few years by an unexplained macrocytic anemia with no evidence of megaloblastic anemia and a mild thrombocytopenia or neutropenia. Clinical symptoms that should prompt ...

see more →

Guidelines  5 results

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myel...
https://doi.org/10.1007/s12185-017-2330-1
International Journal of Hematology; Usui N

Sep 25th, 2017 - JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).|2017|Usui N,|administration & dosage,administration & dosage,administration & dosage,administration &...

Chronic Myelogenous Leukemia, Version 1.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Radich JP et. al.

Nov 15th, 2013 - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring m...

Chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2012.0009
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Abboud CN et. al.

Jan 10th, 2012 - Chronic myelogenous leukemia.|2012|O'Brien S,Abboud CN,Akhtari M,Altman J,Berman E,|therapeutic use,diagnosis,drug therapy,therapy,therapeutic use,

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2009.0065
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Berman E et. al.

Nov 3rd, 2009 - NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.|2009|O'Brien S,Berman E,Borghaei H,Deangelo DJ,Devetten MP,|therapeutic use,diagnosis,drug therapy,surgery,

Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatmen...
https://doi.org/10.1093/annonc/mdn091
Annals of Oncology : Official Journal of the European Soc... Hochhaus A, Dreyling M et. al.

May 9th, 2008 - Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up.|2008|Hochhaus A,Dreyling M, ,|diagnosis,epidemiology,therapy,

see more →

Drugs  20 results see all →

Clinicaltrials.gov  95 results

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04795427

Nov 17th, 2021 - The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of asciminib versus best available therapy (BAT) in Chinese patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP)...

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
https://clinicaltrials.gov/ct2/show/NCT05061017

Nov 9th, 2021 - Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H...

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
https://clinicaltrials.gov/ct2/show/NCT04188405

Oct 28th, 2021 - PRIMARY OBJECTIVE: I. To determine the efficacy of the regimen, as defined by the rate of complete remission (CR) or CR with incomplete count recovery (CRi). SECONDARY OBJECTIVES: I. To determine efficacy outcomes, including rate of minimal residu...

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
https://clinicaltrials.gov/ct2/show/NCT00070499

Sep 28th, 2021 - PRIMARY OBJECTIVES: I. To compare the molecular response rates, as measured by the decrease in breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) transcripts after 12 months of treatment, in patients with previous...

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies
https://clinicaltrials.gov/ct2/show/NCT03888222

Aug 17th, 2021 - This proposal will evaluate the effects of Bosutinib (Bosulif, Pfizer®) treatment - an FDA-approved tyrosine kinase inhibitor that targets c-Abelson (Abl) and Src tyrosine kinases- in patients with DLB. Investigators have demonstrated safety and e...

see more →

News  118 results

Bringing Epigenetic Therapies From Bench to Bedside
https://www.onclive.com/view/bringing-epigenetic-therapies-from-bench-to-bedside

Oct 6th, 2021 - Ronan T. Swords, MD, PhD Pap Corps Endowed Professor in Leukemia Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL Although there have been advances in therapeutics and supportive care, the...

Clinical Edge Journal Scan Commentary: CML September 2021
https://www.mdedge.com/hematology-oncology/article/245751/cml/clinical-edge-journal-scan-commentary-cml-september-2021
Javier Pinilla-Ibarz MD, PhD

Sep 7th, 2021 - Javier Pinilla-Ibarz MD, PhD Chronic myelogenous leukemia ( CML) is a relatively rare leukemia in pediatric population and although allogenic bone marrow transplant used to be commonly used even in the earlier times of TKIs therapy, the superior s.

Hedgehog Signal Inhibition Hope or Hype?
https://www.onclive.com/view/hedgehog_signal_inhibition_1209

Aug 25th, 2021 - Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients. Transient ...

Therapeutic Decision-Making for Primary Myelofibrosis
https://www.onclive.com/view/therapeutic-decision-making-for-primary-myelofibrosis

Jun 29th, 2021 - Ruben Mesa, MD, FACP: Srdan, as we’ve heard about the risk of premature death from myelofibrosis—it’s clearly a major concern, it’s clearly a burden these patients can face—how do you factor in these goals and the burden of disease as you try to c...

Utilizing Next-Generation ALK Inhibitors in NSCLC
https://www.onclive.com/view/utilizing-next-generation-alk-inhibitors-in-nsclc

Apr 2nd, 2021 - For High-Definition, Click There are currently more than 10 next-generation ALK inhibitors in development as potential treatments for patients with non-small cell lung cancer (NSCLC). These newer agents appear to penetrate the CNS and are safe a...

see more →

Patient Education  3 results see all →